Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase NA 3Phase 2 3Phase 3 1

Status

Completed 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1

Conditions

Lymphoma 6HIV Infections 3Acquired Immunodeficiency Syndrome 3Sarcoma, Kaposi 2Multi-centric Castleman's Disease 2Epstein-Barr Virus Infections 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphadenopathy 1Leukemia-Lymphoma, Adult T-Cell 1Hodgkin Disease 1Herpesviridae Infections 1Cytomegalovirus Infections 1Castleman Disease 1AIDS-Related Opportunistic Infections 1

Interventions

Doxorubicin 5Filgrastim 4Zidovudine 3Vincristine 3Etoposide 3Valganciclovir 2Thalidomide 2Rituximab 2Mitoxantrone 2Interferon alpha-2 2Cyclophosphamide 2Bleomycin 2ziconotide 1vesnarinone 1tocilizumab 1tin etiopurpurin 1interferon gamma-1b 1human papillomavirus vaccine, L1 type 16, 18 1Vinblastine 1Tumor Necrosis Factor-alpha 1Sugars 1Semaxinib 1Ro 24-7429 1Ritonavir 1Prednisone 1Paclitaxel 1Nivolumab 1Mitoguazone 1Methotrexate 1Medical Marijuana 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Acquired Immunodeficiency Syndrome × Zidovudine × Clear all
NCT00000712 2021-11-04

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
400 enrolled

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Herpesviridae Infections, HIV Infections, AIDS-Related Opportunistic Infections, Epstein-Barr Virus Infections

NCT00000687 2021-11-03

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
60 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡